je.st
news
Tag: merck
Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets
2013-02-22 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the companys investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042orLesley Brown, 267-305-3545orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
analyses
grass
Merck & Co Stock Rating Reaffirmed by JPMorgan Chase
2013-02-20 16:03:51| Biotech - Topix.net
's stock had its "overweight" rating restated by analysts at JPMorgan Chase in a research report issued to clients and investors on Tuesday.
Tags: rating
stock
chase
merck
Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
2013-02-20 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, South Korea WHITEHOUSE STATION, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. Language: English Contact HTML: Merck Media Relations:Ronald Rogers, 908-423-6449orMerck Investor Relations:Justin Holko, 908-423-5088orSamsung Bioepis:HongSeok Ji, +82-32-455-6102 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: enter
development
agreement
samsung
Merck to pay $688 million to settle Enhance shareholder suits
2013-02-14 22:24:35| Agriculture - Topix.net
Shareholder lawsuits over a failed cholesterol drug have led Merck to settle for $688 million.
Tags: pay
million
enhance
suits
Merck settles investor suits on cholesterol drugs
2013-02-14 18:15:13| Biotech - Topix.net
Merck & Co. has agreed to pay $688 million to settle two lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales.
Tags: drugs
investor
suits
cholesterol
Sites : [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] next »